{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:16:17Z","timestamp":1780395377565,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metabolic tumor volume (MTV) derived from [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT has shown promise in improving preoperative staging and prognostication in endometrial cancer, both as a standalone biomarker and as a foundation for PET-based tumor radiomics. Despite its potential, standardized segmentation methods are lacking. This study aimed to (1) evaluate interobserver agreement in MTV delineation, (2) compare MTVs obtained through various thresholding approaches by examining their correlation with anatomical tumor volume (ATV) from MRI, and (3) assess their value for predicting aggressive disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 146 patients with histologically confirmed endometrial cancer who underwent preoperative PET\/CT imaging on a Siemens TruePoint (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200967) or a Siemens Biograph Vision scanner (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979). MTV\n                      <jats:sub>2.5<\/jats:sub>\n                      defined by a standardized uptake value (SUV) threshold larger than 2.5, demonstrated excellent reproducibility between readers, with an intraclass correlation coefficient (95% confidence interval (CI)) of 0.97 (0.96, 0.98). MTV\n                      <jats:sub>40%<\/jats:sub>\n                      , defined by SUV\u2009&gt;\u200940% of SUV\n                      <jats:sub>max<\/jats:sub>\n                      , yielded an ICC (95% CI) of 0.91 (0.87, 0.93). Both the fixed 2.5 threshold and all relative SUV\n                      <jats:sub>max<\/jats:sub>\n                      -based thresholds (20\u201360% SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) produced MTVs with strong correlation to ATV, with Spearman\u2019s rank correlation coefficients ranging from 0.806 to 0.874 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The closest volumetric match to ATV was observed for MTV\n                      <jats:sub>30%<\/jats:sub>\n                      , with a median difference (95% CI) of -4% (-11%, 2%). In terms of predictive performance, MTV\n                      <jats:sub>2.5<\/jats:sub>\n                      and MTV\n                      <jats:sub>20\u201350%<\/jats:sub>\n                      yielded comparable results for predicting lymph node metastases, advanced FIGO stage (III-IV), and 3-year disease specific survival, with area under receiver operating characteristic curve (AUC) values (95% CI) ranging from 0.68 (0.53, 0.82) to 0.77 (0.65, 0.88). MTV\n                      <jats:sub>60%<\/jats:sub>\n                      showed slightly lower prediction values across all outcomes, with AUCs (95% CI) between 0.64 (0.49, 0.80) and 0.72 (0.63, 0.82).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      MTV\n                      <jats:sub>2.5<\/jats:sub>\n                      has excellent reproducibility and correlates well with anatomical volume. Both MTV\n                      <jats:sub>2.5<\/jats:sub>\n                      and MTV\n                      <jats:sub>20\u201350%<\/jats:sub>\n                      thresholds yield similar performances for predicting aggressive disease features, supporting their potential for clinical implementation in preoperative assessment of endometrial cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01412-0","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:14:34Z","timestamp":1779988474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward reproducible metabolic tumor volume quantification in endometrial cancer: optimizing [\u00b9\u2078F]FDG PET\/CT tumor segmentation methods"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-7870","authenticated-orcid":false,"given":"Kristine Eldevik","family":"Fasmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunniva","family":"Lind\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Andrea","family":"Dybvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend","family":"Hodneland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Krakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingfrid Salvesen","family":"Haldorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1412_CR1","unstructured":"Cancer, Norwegian Institute of Public Health. In Norway 2024 [Internet]. 2025 [cited 2025 Jul 9]. https:\/\/www.fhi.no\/en\/publ\/2025\/cancer-in-norway-2024\/. Accessed 9 Jul 2025."},{"key":"1412_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1514010","volume":"383","author":"KH Lu","year":"2020","unstructured":"Lu KH, Broaddus RR, Massachusetts Medical Society. Endometrial cancer. N Engl J Med. 2020;383:2053\u201364. https:\/\/doi.org\/10.1056\/NEJMra1514010.","journal-title":"N Engl J Med"},{"key":"1412_CR3","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1016\/j.jacr.2020.09.001","volume":"17","author":"C Reinhold","year":"2020","unstructured":"Reinhold C, Ueno Y, Akin EA, Bhosale PR, Dudiak KM, Jhingran A, et al. ACR appropriateness criteria\u00ae pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol. 2020;17:S472-86. https:\/\/doi.org\/10.1016\/j.jacr.2020.09.001.","journal-title":"J Am Coll Radiol"},{"key":"1412_CR4","unstructured":"Forord - Nasjonalt. handlingsprogram med retningslinjer for gynekologisk kreft, 28.06.2021 [Internet]. [cited 2022 Apr 8]. https:\/\/www.helsebiblioteket.no\/retningslinjer\/gynekologisk-kreft\/forord. Accessed 8 Apr 2022."},{"key":"1412_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0506-0","volume":"18","author":"IS Haldorsen","year":"2016","unstructured":"Haldorsen IS, Salvesen HB. What is the best preoperative imaging for endometrial cancer? Curr Oncol Rep. 2016;18:25. https:\/\/doi.org\/10.1007\/s11912-016-0506-0.","journal-title":"Curr Oncol Rep"},{"key":"1412_CR6","doi-asserted-by":"publisher","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021. https:\/\/doi.org\/10.1136\/ijgc-2020-002230.","DOI":"10.1136\/ijgc-2020-002230"},{"key":"1412_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11700-3","author":"S Nougaret","year":"2025","unstructured":"Nougaret S, Sala E, Lakhman Y, Sadowski E, Venkatesan AM, Rockall A, et al. Updated ESUR guidelines for endometrial cancer: integrating MRI with the 2023 FIGO staging revolution. Eur Radiol. 2025. https:\/\/doi.org\/10.1007\/s00330-025-11700-3.","journal-title":"Eur Radiol"},{"key":"1412_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00330-018-5515-y","volume":"29","author":"S Nougaret","year":"2019","unstructured":"Nougaret S, Horta M, Sala E, Lakhman Y, Thomassin-Naggara I, Kido A, et al. Endometrial cancer MRI staging: updated guidelines of the European Society of Urogenital Radiology. Eur Radiol. 2019;29:792\u2013805. https:\/\/doi.org\/10.1007\/s00330-018-5515-y.","journal-title":"Eur Radiol"},{"key":"1412_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2967\/jnumed.115.170597","volume":"57","author":"VR Bollineni","year":"2016","unstructured":"Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, Salvesen HB, Haldorsen IS. High diagnostic value of 18F-FDG PET\/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med. 2016;57:879\u201385. https:\/\/doi.org\/10.2967\/jnumed.115.170597.","journal-title":"J Nucl Med"},{"key":"1412_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00330-019-06622-w","volume":"30","author":"KE Fasmer","year":"2020","unstructured":"Fasmer KE, Gulati A, Dybvik JA, Ytre-Hauge S, Salvesen \u00d8, Trovik J, et al. Preoperative 18F-FDG PET\/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. Eur Radiol. 2020;30:2443\u201353. https:\/\/doi.org\/10.1007\/s00330-019-06622-w.","journal-title":"Eur Radiol"},{"key":"1412_CR11","doi-asserted-by":"publisher","unstructured":"Husby JA, Reitan BC, Biermann M, Trovik J, Bj\u00f8rge L, Magnussen IJ, et al. Metabolic tumor volume on 18F-FDG PET\/CT improves preoperative identification of high-risk endometrial carcinoma patients. J Nucl Med. 2015;56:1191\u20138. https:\/\/doi.org\/10.2967\/jnumed.115.159913.","DOI":"10.2967\/jnumed.115.159913"},{"key":"1412_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/1471-0528.12543","volume":"121","author":"S-H Shim","year":"2014","unstructured":"Shim S-H, Kim D-Y, Lee D-Y, Lee S-W, Park J-Y, Lee JJ, et al. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F\u2013FDG PET\/CT, predict the recurrence of endometrial cancer. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121:1097\u2013106. https:\/\/doi.org\/10.1111\/1471-0528.12543.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"key":"1412_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00259-022-06001-6","volume":"50","author":"M Hatt","year":"2023","unstructured":"Hatt M, Krizsan AK, Rahmim A, Bradshaw TJ, Costa PF, Forgacs A, et al. Joint EANM\/SNMMI guideline on radiomics in nuclear medicine. Eur J Nucl Med Mol Imaging. 2023;50:352\u201375. https:\/\/doi.org\/10.1007\/s00259-022-06001-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07335-7","author":"KE Fasmer","year":"2025","unstructured":"Fasmer KE, Gulati A, Lind\u00e5s S, Krakstad C, Haldorsen IS. Predicting aggressive disease and poor outcome in endometrial cancer using preoperative [18F]FDG PET primary tumor radiomics. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07335-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ygyno.2020.12.002","volume":"160","author":"D Forsse","year":"2021","unstructured":"Forsse D, Berg HF, Bozickovic O, Engerud H, Halle MK, Hoivik EA, et al. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecol Oncol. 2021;160:396\u2013404. https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.002.","journal-title":"Gynecol Oncol"},{"key":"1412_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023;162:383\u201394. https:\/\/doi.org\/10.1002\/ijgo.14923.","journal-title":"Int J Gynecol Obstet"},{"key":"1412_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","volume":"105","author":"W Creasman","year":"2009","unstructured":"Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109. https:\/\/doi.org\/10.1016\/j.ijgo.2009.02.010.","journal-title":"Int J Gynaecol Obstet"},{"key":"1412_CR19","unstructured":"Gynekologisk kreft \u2013. handlingsprogram [Internet]. Helsedirektoratet. [cited 2025 Jan 17]. https:\/\/www.helsedirektoratet.no\/retningslinjer\/gynekologisk-kreft--handlingsprogram. Accessed 17 Jan 2025."},{"key":"1412_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80068-9","volume":"11","author":"E Hodneland","year":"2021","unstructured":"Hodneland E, Dybvik JA, Wagner-Larsen KS, \u0160olt\u00e9szov\u00e1 V, Munthe-Kaas AZ, Fasmer KE, et al. Automated segmentation of endometrial cancer on MR images using deep learning. Sci Rep. 2021;11:179. https:\/\/doi.org\/10.1038\/s41598-020-80068-9.","journal-title":"Sci Rep"},{"key":"1412_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jmri.27444","volume":"53","author":"KE Fasmer","year":"2021","unstructured":"Fasmer KE, Hodneland E, Dybvik JA, Wagner-Larsen K, Trovik J, Salvesen \u00d8, et al. Whole-volume tumor MRI radiomics for prognostic modeling in endometrial cancer. J Magn Reson Imaging. 2021;53:928\u201337. https:\/\/doi.org\/10.1002\/jmri.27444.","journal-title":"J Magn Reson Imaging"},{"key":"1412_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02894-5","volume":"4","author":"EA Hoivik","year":"2021","unstructured":"Hoivik EA, Hodneland E, Dybvik JA, Wagner-Larsen KS, Fasmer KE, Berg HF, et al. A radiogenomics application for prognostic profiling of endometrial cancer. Commun Biol. 2021;4:1363. https:\/\/doi.org\/10.1038\/s42003-021-02894-5.","journal-title":"Commun Biol"},{"key":"1412_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2967\/jnumed.121.262464","volume":"63","author":"F Orlhac","year":"2022","unstructured":"Orlhac F, Eertink JJ, Cottereau A-S, Zijlstra JM, Thieblemont C, Meignan M, et al. A guide to ComBat harmonization of imaging biomarkers in multicenter studies. J Nucl Med. 2022;63:172\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262464.","journal-title":"J Nucl Med"},{"key":"1412_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2010.11.002","volume":"120","author":"HH Chung","year":"2011","unstructured":"Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park N-H, et al. Prognostic value of metabolic tumor volume measured by FDG-PET\/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2010.11.002.","journal-title":"Gynecol Oncol"},{"key":"1412_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s00259-011-1838-5","volume":"38","author":"W Huang","year":"2011","unstructured":"Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET\/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628\u201335. https:\/\/doi.org\/10.1007\/s00259-011-1838-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00259-015-3051-4","volume":"42","author":"JW Kim","year":"2015","unstructured":"Kim JW, Oh JS, Roh J-L, Kim JS, Choi S-H, Nam SY, et al. Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET\/CT in oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015;42:1353\u201361. https:\/\/doi.org\/10.1007\/s00259-015-3051-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.ejrad.2016.03.029","volume":"85","author":"W Shady","year":"2016","unstructured":"Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET\/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: a comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85:1224\u201331. https:\/\/doi.org\/10.1016\/j.ejrad.2016.03.029.","journal-title":"Eur J Radiol"},{"key":"1412_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","volume":"40","author":"C de Van Wiele","year":"2013","unstructured":"de Van Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290\u2013301. https:\/\/doi.org\/10.1007\/s00259-012-2280-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1412_CR29","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00259-020-05136-8","volume":"48","author":"MA Arshad","year":"2021","unstructured":"Arshad MA, Gitau S, Tam H, Park W-H, Patel NH, Rockall A, et al. Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography. Eur J Nucl Med Mol Imaging. 2021;48:2009\u201323. https:\/\/doi.org\/10.1007\/s00259-020-05136-8.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01412-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:33:00Z","timestamp":1780392780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01412-0","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Western Regional Committee for Medical and Health Research Ethics (REK vest 2015\/2333), according to Norwegian legislation and regulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All included patients have given written informed consent at primary diagnosis to participate and publish data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}